Advertisement: TTP Killer 50
20 January, 2011 - 11:59 By News Desk


kymab, antibodies, cambridge

Kymab’s technology is based on research from the Wellcome Trust Sanger Institute and is being commercialised with substantial financial backing from the Wellcome Trust and other global heavyweights, including the Bill & Melinda Gates Foundation.

Its $90 million Series B fund raise was one of the largest pre-clinical rounds in UK biotech history. The company’s technology partnering strategy provides access to Kymouse – a multi-strain, in vivo human monoclonal antibody discovery platform for the creation of fully human monoclonal antibodies and for testing the resulting mAbs in an in vivo preclinical setting.

It is designed to provide the full spectrum of functional human immunoglobin diversity while retaining normal mouse B-cell signalling and maturation.


Newsletter Subscription

Stay informed of the latest news and features